Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center

Articles

Treatment Optimization for Patients With Melanoma

June 23rd 2020

Future Treatment Landscape for Melanoma

June 23rd 2020

Promising Late-Stage Trials in Melanoma

June 23rd 2020

Targeted Therapy Versus IO for Relapsed/Refractory Melanoma

June 23rd 2020

Novel Approaches for Relapsed/Refractory Melanoma

June 23rd 2020

Management of Brain Metastases in Melanoma

June 23rd 2020

I/O Dosing Schedules in Metastatic Melanoma

June 23rd 2020

Novel Therapies for Metastatic Melanoma

June 23rd 2020

Systemic Therapy for Metastatic Melanoma

June 23rd 2020

Adjuvant Therapy for Melanoma: Safety and Efficacy

June 23rd 2020

Adjuvant Therapy for Melanoma: Ongoing Studies of Interest

June 23rd 2020

Adjuvant Data Explored for Locally Advanced Melanoma

June 23rd 2020

Neoadjuvant Data Explored for Locally Advanced Melanoma

June 23rd 2020

pCR and Neoadjuvant Therapy for Melanoma

June 23rd 2020

Molecular Testing in Locally Advanced Melanoma

June 23rd 2020

Identifying Patients for Neoadjuvant Melanoma Therapy

June 23rd 2020

Optimal Management of Locally Advanced Melanoma

June 23rd 2020

Dr. Luke on Predictive Biomarkers in Metastatic Melanoma

February 20th 2020

Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.

Dr. Luke on Current and Emerging Treatment Approaches in Metastatic Melanoma

January 7th 2020

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

ASCO 2015: All About PD-1, But What's Next?

July 29th 2015

At the 2015 ASCO Annual Meeting, we witnessed an extraordinary explosion into the general oncology consciousness of the Programmed Death-1: Programmed Death Ligand-1 axis and drugs that target that interaction.